Contract Manufacturing, Drug Substance, API

Novavax Contracts to Expand Adjuvant Production

June 04, 2020

Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.

More Capacity and Technology Translate to More Options

February 15, 2020

BioPharm International

Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.

Growth in Biologics Market Inspires Outsourcing

February 01, 2020

BioPharm International

CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.

Monitoring and Control of Inline Dilution Processes

August 01, 2019

BioPharm International

Successful process intensification with inline dilution requires effective monitoring and control.

Piramal Pharma Solutions Invests $10 million to Expand HPAPI Capability

June 20, 2019

The company has expanded its high-potency API capability at its Riverview, MI, facility to serve the growing antibody drug conjugates market.

iBio Launches Sterile Fill/Finish Services

June 05, 2019

CDMO iBio introduced cGMP sterile fill/finish services at its facility in Texas.

Thermo Fisher to Acquire Manufacturing Site from GSK

May 16, 2019

The acquisition of GlaxoSmithKline’s manufacturing site in Cork, Ireland, will expand Thermo Fisher Scientific’s global footprint for complex API manufacturing.

Ajinomoto Bio-Pharma Services Expands Services

March 19, 2019

A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.

ADC Bio Secures Additional Equity Round Investment

November 26, 2018

ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.

A Plastic Pipeline for Commercial Bioprocessing?

October 01, 2018

BioPharm International

The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.